Sign in

    Kevin Joaquin

    Research Analyst at Evercore ISI

    Kevin Joaquin is Vice President and Equity Research Analyst at Evercore ISI, specializing in Medical Technology and Life Science Tools & Diagnostics. He covers companies such as HYPR and provides insight on sector trends through participation in quarterly earnings calls, with a focus on financial performance metrics including margin analysis. Joaquin began his finance career at Varian as Finance Business Partner and Investor Relations Specialist before joining Evercore in December 2020; he holds a Bachelor of Science from San Francisco State University. He is registered with FINRA as a securities broker, further supporting his professional credentials in equity research.

    Kevin Joaquin's questions to HOLOGIC (HOLX) leadership

    Kevin Joaquin's questions to HOLOGIC (HOLX) leadership • Q2 2025

    Question

    Kevin Joaquin, on for Vijay Kumar, requested an update on the mammography gantry replacement cycle, including the typical lifespan of units in the field and an assessment of where Hologic is currently within that cycle.

    Answer

    CFO Karleen Oberton explained that Hologic is already in a replacement cycle, as evidenced by its end-of-life strategy. She noted that the average gantry lifespan has extended from a historical 7-9 years to about 10-12 years, due to excellent service and a lack of external catalysts. She characterized the current environment as a steady, ongoing placement of gantries rather than a distinct peak.

    Ask Fintool Equity Research AI

    Kevin Joaquin's questions to NovoCure (NVCR) leadership

    Kevin Joaquin's questions to NovoCure (NVCR) leadership • Q3 2024

    Question

    Kevin Joaquin, on behalf of Vijay Kumar from Evercore ISI, requested further details on the U.S. reimbursement pathway for lung cancer. He specifically asked whether a CMS panel review is anticipated and what the primary barriers to securing coverage might be.

    Answer

    An executive, Frank Leonard, reiterated the expected one to two-year timeline to achieve broad reimbursement across all payers. He confirmed that Novocure is in dialogue with CMS and has multiple pathways to request coverage but stated it was too early to comment on specific steps, such as a formal panel review. He characterized the process as a complex, multi-year program and committed to providing updates as they become available.

    Ask Fintool Equity Research AI